|Bid||12.50 x 800|
|Ask||12.84 x 1100|
|Day's Range||12.16 - 13.21|
|52 Week Range||0.22 - 14.25|
|Beta (5Y Monthly)||1.29|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We have processed the filings of the more than 700 world-class investment firms that we track and now have access to the collective wisdom contained in […]
Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it will host an Analyst & Investor Event on Sunday, December 8th at 7:00 am ET to discuss newly reported clinical data for momelotinib that will be presented at the 61st American Society of Hematology (ASH) Annual Meeting in Orlando, Florida.
Sierra Oncology, Inc. (Nasdaq: SRRA), a late-stage drug development company focused on the development and commercialization of momelotinib, a JAK1, JAK2 & ACVR1 inhibitor with a potentially differentiated therapeutic profile for the treatment of myelofibrosis, today announced that it has closed its previously announced underwritten public offering, with gross proceeds to Sierra Oncology of $103 million.
The big shareholder groups in Sierra Oncology, Inc. (NASDAQ:SRRA) have power over the company. Institutions will often...
We often see insiders buying up shares in companies that perform well over the long term. On the other hand, we'd be...
You probably know from experience that there is not as much information on small-cap companies as there is on large companies. Of course, this makes it really hard and difficult for individual investors to make proper and accurate analysis of certain small-cap companies. However, well-known and successful hedge fund managers like Jeff Ubben, George Soros […]
The Vancouver, British Columbia-based company said it had a loss of 17 cents per share. The company's shares closed at $1.49. A year ago, they were trading at $1.99. _____ This story was generated by Automated ...
Sierra Oncology, Inc. (NASDAQ:SRRA) shareholders should be happy to see the share price up 18% in the last quarter. But that is meagre solace in the face of the shocking decline over three years. To wit, the share price sk...